The decrease in tumor-associated production of VEGF and blood vessel density by celecoxib could be one of the major mechanisms by which it reduces angiogenesis and inhibits overall ovarian cancer growth in the KpB mouse model. This evidence concerns the gene VEGFA and ovarian cancer.